Appraisal Results for Kymriah, Trelegy Up for Chuikyo Review on March 24; Price Cuts Likely

For the first time, the health ministry will present appraisal results under its cost-effectiveness assessment (CEA) scheme to a key reimbursement policy council on March 24, which will cover Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) and GlaxoSmithKline’s COPD therapy Trelegy...read more